Plain-English translation of NCT06532006 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called , which is designed to target cancer cells in advanced stomach and gastroesophageal junction cancer. will be combined with two standard treatments you would likely receive anyway: an established antibody drug called and chemotherapy (XELOX). The study wants to see if adding this medication to your standard care helps patients live longer and feel better.
Even with current treatments, advanced stomach cancer remains very difficult to treat. This trial is exploring whether the new treatment can improve results by attacking cancer cells in a different way than existing options, potentially offering patients a better chance at controlling their disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the new medication or a placebo (inactive substance), both combined with and chemotherapy. All treatments are given as infusions every 3 weeks. You will visit the clinic regularly for infusions, blood tests, and imaging scans to check how well the treatment is working. The trial involves 550 people total, and you will be randomly assigned to either the treatment group or the control group — neither you nor your doctors will know which group you're in at first.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States